SCHEMBL2045392

SCHEMBL2045392

COc1ccc(Cc2c(C)[nH][nH]c2=O)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.42
MAPT P10636 4/20 0.41
TDP2 O95551 1/20 0.41
POLB P06746 1/20 0.41
PDE10A Q9Y233 3/20 0.39
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.36
DAO P14920 2/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
HTR1D P28221 1/20 0.35
HTR6 P50406 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4593860 0.86 HSD17B10 (0.41) GAAMAPTPOLBPDE10AKMT2A
SCHEMBL4593547 0.85 LMNA (0.39) GAAMAPTPOLBKDM4EDAO
SCHEMBL4593736 0.82 TAAR1 (0.45) GAAMAPTTDP2POLBPDE10A
SCHEMBL4593415 0.82 DAO (0.38) GAAMAPTKMT2AKDM4EDAO
SCHEMBL14626458 0.80 GAA (0.40) GAAMAPTPOLBKMT2AKDM4E
SCHEMBL2254318 0.76 ERAP1 (0.51) GAAMAPTPOLBKMT2ADAO
SCHEMBL4593543 0.76 GAA (0.37) GAAMAPTPDE10AKMT2ADAO
SCHEMBL2788150 0.75 DAO (0.38) GAAMAPTPDE10AKMT2AKDM4E
SCHEMBL3747730 0.75 KMT2A (0.34) MAPTPOLBPDE10AKMT2AKDM4E
SCHEMBL3779266 0.73 ALDH1A1 (0.42) GAAMAPTPOLBPDE10AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956041-B2 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide AJINOMOTO CO., INC. (JP) 2011-06-07 US disclosed
EP-2163555-A1 New pyrazole derivatives and diabetic medicine containing them Ajinomoto Co., Inc. (JP) 2010-03-17 EP disclosed
US-20100063124-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM AJINOMOTO CO., INC. (JP) 2010-03-11 US disclosed
EP-1338603-B1 NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME AJINOMOTO KK (JP) 2010-01-20 EP disclosed
US-7645787-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2010-01-12 US disclosed
EP-1910391-A1 PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES Boehringer Ingelheim International GmbH (DE) 2008-04-16 EP disclosed
US-20080020987-A1 Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes AJINOMOTO CO., INC. (JP) 2008-01-24 US disclosed
US-20080020987-A1 Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes AJINOMOTO CO., INC. (JP) 2008-01-24 US disclosed
US-20080020987-A1 Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes AJINOMOTO CO., INC. (JP) 2008-01-24 US disclosed
US-20070270479-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM AJINOMOTO CO. INC (JP) 2007-11-22 US disclosed
WO-2007010015-A1 PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-25 WO disclosed
WO-2007010015-A1 PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-25 WO disclosed
US-7015201-B2 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO., INC. (JP) 2006-03-21 US disclosed
US-20060058244-A1 New pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2006-03-16 US disclosed
US-20050143424-A1 Prophylactic and therapeutic agent of diabetes mellitus AJINOMOTO CO. INC (JP) 2005-06-30 US disclosed
US-20050043249-A1 New pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2005-02-24 US disclosed
EP-1500403-A1 PREVENTIVE/REMEDY FOR DIABETES Ajinomoto Co., Inc. (JP) 2005-01-26 EP disclosed
US-6815428-B2 AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-09 US disclosed
US-20040006025-A1 Pyrazole derivatives and diabetic medicine containing them AJINOMOTO CO. INC (JP) 2004-01-08 US disclosed
EP-1338603-A1 NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2003-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006025-A1 Pyrazole derivatives and diabetic medicine containing them SLC5A2, SLC5A1, DPP4 GAA 1092/4885MAPT 4069/4885TDP2 4342/4885
US-20070270479-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM DPP4, SLC5A2, SLC5A1 GAA 1302/4885MAPT 4248/4885TDP2 4406/4885
US-20060058244-A1 New pyrazole derivatives and diabetic medicine containing them DPP4, SLC5A2, SLC5A1 GAA 1302/4885MAPT 4248/4885TDP2 4406/4885
US-20080020987-A1 Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes CYP4B1, CYP1B1, CYP11B1 GAA 368/4885MAPT 4364/4885TDP2 3852/4885
US-20100063124-A1 NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM DPP4, SLC5A2, SLC5A1 GAA 1302/4885MAPT 4248/4885TDP2 4406/4885
US-20050043249-A1 New pyrazole derivatives and diabetic medicine containing them DPP4, SLC5A2, SLC5A1 GAA 1302/4885MAPT 4248/4885TDP2 4406/4885
US-20050143424-A1 Prophylactic and therapeutic agent of diabetes mellitus SLC5A2, SLC5A1, GPR119 GAA 40/4885MAPT 4851/4885TDP2 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.